GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » PB Ratio

Lantheus Holdings (FRA:0L8) PB Ratio : 5.71 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-15), Lantheus Holdings's share price is €71.66. Lantheus Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was €12.55. Hence, Lantheus Holdings's PB Ratio of today is 5.71.

The historical rank and industry rank for Lantheus Holdings's PB Ratio or its related term are showing as below:

FRA:0L8' s PB Ratio Range Over the Past 10 Years
Min: 1.41   Med: 7.65   Max: 38.25
Current: 5.71

During the past 13 years, Lantheus Holdings's highest PB Ratio was 38.25. The lowest was 1.41. And the median was 7.65.

FRA:0L8's PB Ratio is ranked worse than
86.42% of 957 companies
in the Drug Manufacturers industry
Industry Median: 2.02 vs FRA:0L8: 5.71

During the past 12 months, Lantheus Holdings's average Book Value Per Share Growth Rate was 109.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 15.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 39.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lantheus Holdings was 131.80% per year. The lowest was 13.90% per year. And the median was 35.20% per year.

Back to Basics: PB Ratio


Lantheus Holdings PB Ratio Historical Data

The historical data trend for Lantheus Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings PB Ratio Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.85 1.79 4.35 7.55 5.12

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.15 10.24 6.87 5.12 4.41

Competitive Comparison of Lantheus Holdings's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's PB Ratio falls into.



Lantheus Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Lantheus Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=71.66/12.553
=5.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Lantheus Holdings  (FRA:0L8) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Lantheus Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (FRA:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines